Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanadrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanadrel SCHEMBL180963 | 1.00 | HTR1A (0.44) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| Guanadrel SCHEMBL23858338 | 0.98 | HTR1A (0.43) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| Guanadrel SCHEMBL30302017 | 0.93 | ADRA1D (0.40) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| Guanadrel SCHEMBL41051 | 0.93 | ADRA1D (0.40) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| Guanadrel SCHEMBL4440330 | 0.86 | GAA (0.42) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| SCHEMBL8192982 | 0.72 | PABPC1 (0.53) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| SCHEMBL1487109 | 0.72 | PABPC1 (0.53) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| SCHEMBL8325616 | 0.72 | PABPC1 (0.53) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| SCHEMBL714617 | 0.72 | PABPC1 (0.53) | HTR1AADRA1DADRA1BPABPC1CTDSP1 | |
| SCHEMBL8625830 | 0.72 | PABPC1 (0.53) | HTR1AADRA1DADRA1BPABPC1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| US-9833618-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2017-12-05 | — | — | US | disclosed |
| US-20140350041-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2014-11-27 | — | — | US | disclosed |
| US-8788041-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110029030-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2011-02-03 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060206149-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-09-14 | — | — | US | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |